Addition of Pegilodecakin to FOLFOX Did Not Improve OS in Metastatic Pancreatic Cancer

A phase 3 study evaluating second-line therapy with pegilodecakin, a pegylated form of interleukin-10 (IL-10), in combination with FOLFOX compared with FOLFOX alone in patients with metastatic pancreatic adenocarcinoma (PDAC) did not meet its primary endpoint, according to results presented at the 2020 Gastrointestinal Cancers Symposium in San Francisco, California.